Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'
- PMID: 32816688
- DOI: 10.1136/annrheumdis-2020-218029
Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'
Keywords: arthritis, psoriatic; biological therapy; cytokines; inflammation; therapeutics.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Response to: 'Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina et al.Ann Rheum Dis. 2021 May;80(5):e80. doi: 10.1136/annrheumdis-2020-218147. Epub 2020 Aug 18. Ann Rheum Dis. 2021. PMID: 32816687 No abstract available.
Comment on
-
Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept.Ann Rheum Dis. 2020 Sep;79(9):1251-1252. doi: 10.1136/annrheumdis-2020-217362. Epub 2020 Apr 30. Ann Rheum Dis. 2020. PMID: 32354772 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical